![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Department of Drug Metabolism (X.-Y.C., J.R.S., J.L., D.J.N., X.C., R.W.W., J.Y., D.P.H., D.C.E., R.E.) and Laboratory Animal Resources (M.A.M.), Merck & Co., Rahway, New Jersey
The multidrug resistance protein Mrp2 is an ATP-binding cassette (ABC) transporter mainly expressed in liver, kidney, and intestine. One of the physiological roles of Mrp2 is to transport bilirubin glucuronides from the liver into the bile. Current in vivo models to study Mrp2 are the transporter-deficient and Eisai hyperbilirubinemic rat strains. Previous reports showed hyperbilirubinemia and induction of Mrp3 in the hepatocyte sinusoidal membrane in the mutant rats. In addition, differences in liver cytochrome P450 and UGT1a levels between wild-type and mutant rats were detected. To study whether these compensatory mechanisms were specific to rats, we characterized Mrp2–/– mice. Functional absence of Mrp2 in the knockout mice was demonstrated by showing increased levels of bilirubin and bilirubin glucuronides in serum and urine, a reduction in biliary excretion of bilirubin glucuronides and total glutathione, and a reduction in the biliary excretion of the Mrp2 substrate dibromosulfophthalein. To identify possible compensatory mechanisms in Mrp2–/– mice, the expression levels of 98 phase I, phase II, and transporter genes were compared in liver, kidney, and intestine of male and female Mrp2–/– and control mice. Unlike in Mrp2 mutant rats, no induction of Mrp3 in Mrp2–/– mice was detected. However, Mrp4 mRNA and protein in liver and kidney were increased 
6- and 2-fold, respectively. Phenotypic analysis of major cytochrome P450-mediated activities in liver microsomes did not show differences between wild-type and Mrp2–/– mice. In conclusion, Mrp2–/– mice are a new valuable tool to study the role of Mrp2 in drug disposition.
Address correspondence to: Dr. Xiaoyan Chu, Merck & Co., RY80, 126 E. Lincoln Ave., Rahway, NJ 07065. E-mail: xiaoyan_chu{at}merck.com
This article has been cited by other articles:
|
|
 |
|
  K. K. Bhargava, B. Joseph, M. Ananthanarayanan, N. Balasubramaniyan, G. G. Tronco, C. J. Palestro, and S. Gupta Adenosine Triphosphate-Binding Cassette Subfamily C Member 2 Is the Major Transporter of the Hepatobiliary Imaging Agent 99mTc-Mebrofenin J. Nucl. Med., July 1, 2009; 50(7): 1140 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tsuda, T. Terada, T. Mizuno, T. Katsura, J. Shimakura, and K.-i. Inui Targeted Disruption of the Multidrug and Toxin Extrusion 1 (Mate1) Gene in Mice Reduces Renal Secretion of Metformin Mol. Pharmacol., June 1, 2009; 75(6): 1280 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L.H. Vlaming, Z. Pala, A. van Esch, E. Wagenaar, D. R. de Waart, K. van de Wetering, C. M.M. van der Kruijssen, R. P.J. Oude Elferink, O. van Tellingen, and A. H. Schinkel Functionally Overlapping Roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the Elimination of Methotrexate and Its Main Toxic Metabolite 7-Hydroxymethotrexate In vivo Clin. Cancer Res., May 1, 2009; 15(9): 3084 - 3093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wang, M. Leggas, M. Goswami, P. E. Empey, and P. J. McNamara N-(4-[2-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine Carboxamide (GF120918) As a Chemical ATP-Binding Cassette Transporter Family G Member 2 (Abcg2) Knockout Model to Study Nitrofurantoin Transfer into Milk Drug Metab. Dispos., December 1, 2008; 36(12): 2591 - 2596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. D. Lehman-McKeeman Beam Me Up Scotty: Incorporating Transporters in Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling Toxicol. Sci., July 1, 2008; 104(1): 1 - 3. [Full Text] [PDF]
|
|
|
|
|
|
S. Matsushima, K. Maeda, H. Hayashi, Y. Debori, A. H. Schinkel, J. D. Schuetz, H. Kusuhara, and Y. Sugiyama Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine Mol. Pharmacol., May 1, 2008; 73(5): 1474 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zimmermann, K. van de Wetering, E. van de Steeg, E. Wagenaar, C. Vens, and A. H. Schinkel Species-Dependent Transport and Modulation Properties of Human and Mouse Multidrug Resistance Protein 2 (MRP2/Mrp2, ABCC2/Abcc2) Drug Metab. Dispos., April 1, 2008; 36(4): 631 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Tian, M. J. Zamek-Gliszczynski, J. Li, A. S. Bridges, K.-i. Nezasa, N. J. Patel, T. J. Raub, and K. L. R. Brouwer Multidrug Resistance-Associated Protein 2 Is Primarily Responsible for the Biliary Excretion of Fexofenadine in Mice Drug Metab. Dispos., January 1, 2008; 36(1): 61 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. van de Wetering, N. Zelcer, A. Kuil, W. Feddema, M. Hillebrand, M. L. H. Vlaming, A. H. Schinkel, J. H. Beijnen, and P. Borst Multidrug Resistance Proteins 2 and 3 Provide Alternative Routes for Hepatic Excretion of Morphine-Glucuronides Mol. Pharmacol., August 1, 2007; 72(2): 387 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Takenaka, J. A. Morgan, G. L. Scheffer, M. Adachi, C. F. Stewart, D. Sun, M. Leggas, K. F.K. Ejendal, C. A. Hrycyna, and J. D. Schuetz Substrate Overlap between Mrp4 and Abcg2/Bcrp Affects Purine Analogue Drug Cytotoxicity and Tissue Distribution Cancer Res., July 15, 2007; 67(14): 6965 - 6972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ninomiya, K. Ito, R. Hiramatsu, and T. Horie Functional Analysis of Mouse and Monkey Multidrug Resistance-Associated Protein 2 (Mrp2) Drug Metab. Dispos., December 1, 2006; 34(12): 2056 - 2063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Zamek-Gliszczynski, K.-i. Nezasa, X. Tian, A. S. Bridges, K. Lee, M. G. Belinsky, G. D. Kruh, and K. L. R. Brouwer Evaluation of the Role of Multidrug Resistance-Associated Protein (Mrp) 3 and Mrp4 in Hepatic Basolateral Excretion of Sulfate and Glucuronide Metabolites of Acetaminophen, 4-Methylumbelliferone, and Harmol in Abcc3-/- and Abcc4-/- Mice J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1485 - 1491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Zamek-Gliszczynski, K.-i. Nezasa, X. Tian, J. C. Kalvass, N. J. Patel, T. J. Raub, and K. L. R. Brouwer The Important Role of Bcrp (Abcg2) in the Biliary Excretion of Sulfate and Glucuronide Metabolites of Acetaminophen, 4-Methylumbelliferone, and Harmol in Mice Mol. Pharmacol., December 1, 2006; 70(6): 2127 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. H. Vlaming, K. Mohrmann, E. Wagenaar, D. R. de Waart, R. P. J. O. Elferink, J. S. Lagas, O. van Tellingen, L. D. Vainchtein, H. Rosing, J. H. Beijnen, et al. Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 319 - 327. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
